PubMed دسترسی آزاد

Deciphering the Medicinal Chemistry Aspects of Akt Inhibitors for the Management of Cancer: Structure-Activity Relationship Frameworks, Landscapes, and Optimization Approaches.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

The Akt pathway is dysregulated in cancer, leading to proliferation, decreased apoptosis, and metastasis, and hence is a major therapeutic target in cancer treatment. Over the past two decades, substantial advances have been made in the design of potent, selective, and pharmacokinetically optimized Akt inhibitors. This review analyzes recent Akt inhibitors, with particular focus on the structure-activity relationship (SAR) of their heterocyclic core scaffolds and the resulting biological activity. Additional strategies identified in this review that have yielded promising preclinical and clinical candidates include scaffold optimization, conformational restriction, and hybrid design. Special emphasis is given to advanced inhibitors such as capivasertib, ipatasertib, and NTQ1062, which illustrate the influence of pharmacophoric refinement on therapeutic success. In this review, we integrate knowledge of medicinal chemistry and structure to direct the rational design of next generation Akt inhibitors that are safer and more effective for targeted cancer therapy.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

کلیدواژه‌ها

Akt inhibitorscapivasertibheterocyclic scaffoldsstructure–activity relationships
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Formulation, evaluation and characterization of fexofenadine IR and paracetamol SR multiparticulate drug delivery system.

BACKGROUND: Multiparticulate Drug Delivery (MDD) system are particularly considered as well suited systems for controlling oral preparations that have low risk of dose-dumping. OBJECTIVES: The current research work was aimed to prepare Fexofenadine HCl immediate release (IR) and Paracetamol sustained release (SR) pellets in a single dosage unit for the treatment of Allergic Rhinitis. Extrusion-spheronization was used to fabricate pelle…

PubMed2026

Molecular Design and Anticancer Activities of Small-Molecule BRAF Inhibitors: A Medicinal Chemistry Perspective.

BRAF is a cytoplasmic serine-threonine protein kinase that plays a critical role in the MAPK signaling pathway. BRAF is the only member of the RAF family activated by mutation in human cancers. Many classes of B-Raf small molecule inhibitors have been identified. In this review, we will highlight typical BRAF inhibitors developed during these decades and provide a reference for the exploration of more potential BRAF inhibitors in the f…

PubMed2026

Medicinal Chemistry Aspects of Thiazole and Thiazolidine Derivatives as Fundamental Building Blocks to Design New NNRTIs Against HIV-1 Reverse Transcriptase.

The therapy to treat the Human Immunodeficiency virus (HIV) and decrease the viral load has been a challenge since its discovery due to its ability to mutate, escape from drug therapies, and immunologic system. Consequently, the development of new therapies, especially potential molecules that focus on specific viral mechanisms to block viral replication, became a critical challenge in recent decades. The Reverse Transcriptase (RT) is …

PubMed2026

Glutamine-tagged Sorafenib and Atorvastatin Coloaded Polymeric Nanoparticles for Hybrid Cell Death Induction in Colorectal Cancer: Part I Formulation, Characterization, In-vitro/In-vivo Safety and Efficacy Evaluation.

The present study explores the potential of sorafenib (SOR) and atorvastatin (ATST) to induce a ferroptosis and apoptosis-based hybrid cell death mechanism. The synergistic ATST + SOR combination was delivered through Glutamine-tagged PLGA nanoparticles (ATST + SOR/G-PLGA NPs) to promote intratumoral specificity. The formulation was optimized using DesignExpert® software by adopting Box-Behnken design (BBD). The optimized ATST + SOR/G-…